LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Search

Accuray Inc

Fechado

SetorSaúde

0.39 -4.88

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.38

Máximo

0.42

Indicadores-chave

By Trading Economics

Rendimento

7.9M

-14M

Vendas

8.3M

102M

EPS

-0.108

Margem de lucro

-13.468

Funcionários

990

EBITDA

7M

-3.3M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+376.19% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de abr. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-33M

58M

Abertura anterior

5.27

Fecho anterior

0.39

Sentimento de Notícias

By Acuity

50%

50%

156 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Accuray Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de mar. de 2026, 22:42 UTC

Ganhos

Prudential PLC 2025 Adjusted Operating Profit Rises

17 de mar. de 2026, 21:40 UTC

Ganhos

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 de mar. de 2026, 23:56 UTC

Conversa de Mercado

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 de mar. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

17 de mar. de 2026, 23:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de mar. de 2026, 23:42 UTC

Conversa de Mercado

RBA's Return to Policy Tightening Will Work -- Market Talk

17 de mar. de 2026, 23:38 UTC

Conversa de Mercado

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 de mar. de 2026, 23:24 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

17 de mar. de 2026, 23:24 UTC

Conversa de Mercado

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 de mar. de 2026, 22:22 UTC

Conversa de Mercado

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 de mar. de 2026, 22:20 UTC

Ganhos

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 de mar. de 2026, 22:20 UTC

Ganhos

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 de mar. de 2026, 22:07 UTC

Ganhos

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 de mar. de 2026, 22:05 UTC

Ganhos

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 de mar. de 2026, 22:04 UTC

Ganhos

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 de mar. de 2026, 22:03 UTC

Ganhos

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 de mar. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 de mar. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 de mar. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 de mar. de 2026, 21:26 UTC

Ganhos

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 de mar. de 2026, 21:09 UTC

Ganhos

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 de mar. de 2026, 21:08 UTC

Ganhos

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 de mar. de 2026, 21:08 UTC

Ganhos

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 de mar. de 2026, 21:07 UTC

Ganhos

Couche-Tard 3Q EPS 82c >ATD.T

17 de mar. de 2026, 21:06 UTC

Ganhos

Couche-Tard 3Q Rev $21.8B >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q Rev $21.8B >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q EPS 82c >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q Net $757.2M >ATD.T

17 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Energy & Utilities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Accuray Inc Previsão

Preço-alvo

By TipRanks

376.19% parte superior

Previsão para 12 meses

Média 2 USD  376.19%

Máximo 2 USD

Mínimo 2 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Accuray Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.28 / 1.61Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

156 / 351 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Accuray Inc

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
help-icon Live chat